Economy

Indonesia finds some medicines with ingredients linked to fatal child kidney injury

VECTORPOUCH-FREEPIK

JAKARTA — Some medicinal syrups available in Indonesia contained ingredients linked to fatal acute kidney injury (AKI) in children, its health minister said on Thursday, as it investigates a spike in cases and 99 child deaths this year.

Indonesia has temporarily banned sales of all syrup-based medications and has been looking closely at paracetamol syrups used locally to treat fever in children that contain diethylene glycol and ethylene glycol.

Gambia’s government is also investigating child AKI deaths linked to paracetamol syrups after 70 fatalities there. The syrups were made by New Delhi-based Maiden Pharmaceuticals Ltd, which India said it is .

Indonesia’s food and drug agency has said those particular products were not available locally.

Ethylene glycol and diethylene glycol were detected in products found at the homes of some of the patients, health minister Budi Gunadi Sadikin said on Thursday, without specifying how many.

“Some syrups that were used by AKI child patients under five were proven to contain ethylene glycol and diethylene glycol that were not supposed to be there, or of very little amount,” he said.

As of Thursday, Indonesia has identified 206 AKI child cases of which 99 were fatalities this year. Mr. Budi said the real number of cases could be higher than reported.

A health ministry spokesperson declined to say in how many child AKI patients the ingredients were detected, citing the ongoing investigation. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Your daily news source covering investing ideas, market stocks, business, retirement tips from Wall St. to Silicon Valley.

Disclaimer:

TheProficientInvestor.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 TheProficientInvestor. All Rights Reserved.

To Top